VIDEO: Anti-VEGF biosimilars may offer cost savings, accessibility for AMD treatment
Click Here to Manage Email Alerts
SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses an update on the use of anti-VEGF biosimilars for the treatment of age-related macular degeneration.
One large study, presented at the ARVO annual meeting in the AMD: Clinical Research I session, evaluated the efficacy and safety of anti-VEGF biosimilars vs. reference drugs.
Biosimilars were comparable to the reference drugs in terms of effectiveness and safety for the treatment of neovascular AMD, Lad said.
“This affords us an opportunity as clinicians for cost savings and increased accessibility of treatment to patients worldwide,” she said.
Lad noted there is a lack of data on long-term safety and impact on quality of life of these biosimilars.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts